Loading
DT
Dynavax Technologies Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Myers Scott Dunseth, was filed 25 Aug 2025.
Dynavax Technologies Corp: what insiders have been doing
This page follows insider dealings at Dynavax Technologies Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 22 October 2026, 55 filings were filed, from 13 insiders.
All open-market trades in the period are sales: 2 sales worth €1.9M, by 1 insider, with no purchase on record. Biggest ticket of the year: €1.5M, sold by Novack David F and made public on 20 January 2026.
With 55 filings in twelve months, the company is more active than the median of 24 filings across the 3,171 companies we follow on the same exchange. Since 2016, the database holds 10 purchases and 105 sales by insiders of the company.
The median gap between a trade and its publication by SEC (Form 4) is 5 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
472
Thresholds
n/a
Buy Volume
€5M
10 ops. · all time
Sell Volume
€181M
105 ops. · all time
Who traded when
BuySaleDavid F. Novack5 sales
Deep Track Biotechnology Master Fund, Ltd.2 sales
Scott Dunseth Myers1 buy
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$238.7M
Net incomeUS$23.5M9.9% margin
Last declaration on 11 February 2026
Declarations472 total
15,726,349 sharesCommon Stock, par value $0.001 per shareSEC:0001193125-26-046675:0
21,829 sharesCommon Stock - Restricted Stock UnitsSEC:0001073407-26-000002:1
67,860 sharesCommon Stock - Performance Stock UnitsSEC:0001573072-26-000002:1
67,860 sharesCommon Stock - Performance Stock UnitsSEC:0001573072-26-000002:2
56,364 sharesCommon Stock - Performance Stock UnitsSEC:0001573072-26-000002:3
56,364 sharesCommon Stock - Performance Stock UnitsSEC:0001573072-26-000002:4
31,204 sharesCommon Stock - Restricted Stock UnitsSEC:0001356256-26-000002:1
46,430 sharesCommon Stock - Performance Stock UnitsSEC:0001781117-26-000002:1
46,430 sharesCommon Stock - Performance Stock UnitsSEC:0001781117-26-000002:2
42,424 sharesCommon Stock - Performance Stock UnitsSEC:0001781117-26-000002:3
42,424 sharesCommon Stock - Performance Stock UnitsSEC:0001781117-26-000002:4
50,000 sharesCommon Stock - Performance Stock UnitsSEC:0001475990-26-000002:1
50,000 sharesCommon Stock - Performance Stock UnitsSEC:0001475990-26-000002:2
42,424 sharesCommon Stock - Performance Stock UnitsSEC:0001475990-26-000002:3
42,424 sharesCommon Stock - Performance Stock UnitsSEC:0001475990-26-000002:4
165,000 sharesCommon Stock - Performance Stock UnitsSEC:0001777938-26-000004:1
165,000 sharesCommon Stock - Performance Stock UnitsSEC:0001777938-26-000004:2
136,000 sharesCommon Stock - Performance Stock UnitsSEC:0001777938-26-000004:3
136,000 sharesCommon Stock - Performance Stock UnitsSEC:0001777938-26-000004:4
69,634 sharesCommon StockSEC:0001475990-26-000002:0
3,800 sharesCommon StockSEC:0001356256-26-000002:0
7,129 sharesCommon StockSEC:0002067729-26-000002:0
60,204 sharesCommon StockSEC:0001781117-26-000002:0
379,620 sharesCommon StockSEC:0001777938-26-000004:0
63,334 sharesCommon StockSEC:0001573072-26-000002:0
25 of 472 declarations
About Dynavax Technologies Corp
Dynavax Technologies Corp. is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States, with headquarters in Emeryville, California. For European investors, DVAX stands out less as an early-stage biotech and more as a commercial vaccine company with an established revenue base. Its core business is built around the development and commercialization of innovative vaccines using its proprietary CpG 1018 adjuvant technology, which is designed to enhance immune response. The company’s origins are rooted in Toll-like Receptor (TLR) science, and over time Dynavax has evolved from a research-driven biotech into a commercial-stage vaccine player.
The company’s lead product is HEPLISAV-B, an adult hepatitis B vaccine. This asset is the main commercial engine for Dynavax and gives the company a meaningful position in the U.S. adult hepatitis B market. In addition to HEPLISAV-B, Dynavax highlights CpG 1018 as a core platform asset. The adjuvant is used in its marketed product and may also be leveraged in partnerships or external vaccine-development programs. This combination of a marketed vaccine and a proprietary enabling technology is central to the investment thesis.
Read moreShow less
From a competitive perspective, Dynavax occupies a specialist niche in infectious-disease vaccines. Its differentiation comes from the adjuvant platform, which can potentially improve vaccine performance and make its technology attractive to partners. That gives DVAX a more durable strategic profile than a pure development-stage biotech. At the same time, the company remains relatively concentrated: performance is still heavily tied to HEPLISAV-B and to the ability of CpG 1018 to generate broader commercial or partnership value.
Geographically, Dynavax remains primarily U.S.-focused, although it also operates and collaborates internationally through development relationships and selected European activities. In practical terms, the business is centered on vaccines and immunology rather than a broad diversified pharma portfolio. Recent company disclosures have pointed to strong HEPLISAV-B momentum in 2024, including year-over-year growth in net product revenue and approximately 44% U.S. market share at year-end 2024, according to company communications. That operating progress, together with ongoing SEC Form 4 insider transaction filings, keeps DVAX on the radar of investors tracking both fundamentals and insider activity. Overall, Dynavax is best viewed as a health-care / pharma stock with a hybrid profile: a commercial vaccine business supported by a differentiated adjuvant platform and further upside potential from pipeline and partnership execution.
